<DOC>
	<DOCNO>NCT02862535</DOCNO>
	<brief_summary>The primary objective study characterize safety tolerability andecaliximab monotherapy combination S-1 cisplatin chemotherapy Japanese participant inoperable advanced recurrent gastric recurrent gastroesophageal junction ( GEJ ) adenocarcinoma .</brief_summary>
	<brief_title>Andecaliximab Monotherapy Combination With Chemotherapy Japanese Participants With Gastric Gastroesophageal Junction Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Key Must bear Japan must live outside Japan period &gt; 1 year 5 year prior Day 1 Must able trace maternal paternal ancestry parent grandparent ethnically Japanese Histologically confirm inoperable advanced gastric adenocarcinoma ( include adenocarcinoma GEJ ) relapse gastric adenocarcinoma Human Epidermal Growth Factor Receptor 2 ( HER2 ) negative tumor ( primary tumor metastatic lesion ) Monotherapy cohort : Prior antitumor therapy cytotoxic chemotherapy acceptable . Individuals eligible receive standard treatment enroll study . Combination therapy cohort : Prior antitumor therapy cytotoxic chemotherapy acceptable . Individuals must chemonaive metastatic setting . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 1 Adequate baseline organ function ( within 28 day prior Day 1 ) Coagulation : International Normalized Ratio ( INR ) ≤ 1.6 ( unless receive anticoagulation therapy ) . For female childbearing potential , willingness use protocolrecommended method contraception screen visit throughout study treatment period 90 day follow last dose andecaliximab For male childbearing potential intercourse female childbearing potential , willingness use protocolrecommended method contraception start andecaliximab , throughout study treatment period , 90 day follow last dose andecaliximab Willingness comply schedule visit , drug administration plan , image study , laboratory test , study procedure , study restriction Key History evidence clinically significant disorder , condition , disease , opinion investigator medical monitor would pose risk participant safety interfere study evaluation , procedure , completion Pregnant lactating . Enrollment lactate female discontinuation breastfeed acceptable . Individuals known central nervous system ( CNS ) metastases , unless metastasis treat stable individual require systemic steroid Myocardial infarction , symptomatic congestive heart failure ( New York Heart Association Classification &gt; Class II ) , unstable angina , serious uncontrolled cardiac arrhythmia within last 6 month Day 1 Serious systemic fungal , bacterial , viral , infection control require IV antibiotic Individuals know positive human immunodeficiency virus ( HIV ) , hepatitis C infection ( per local standard diagnostic criterion ) , acute chronic hepatitis B infection ( per local standard diagnostic criterion ) NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>